…n thymocytes, lymphocytes, monocytes and eosinophils. Early data suggested that the agent could reduce disability (Coles et al. J Neurol 2006; 253: 98-108), which led to the phase II CAMMS223 trial comparing alemtuzumab with beta-interferon-1a (CAMMS223 Investigators. N Engl J Med 2008; 359: 1786-1801). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter wit…

…REPORT FROM THE 25th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009 – Three studies at the 25th ECTRIMS congress presented new data on vitamin D and multiple sclerosis. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…